USPTO serial 99896059
SEPTERNA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- CASE, LEIGH CAROLINE
- Law office
- TMO LAW OFFICE 112
What this means
Status 638 means your application has been assigned to a USPTO examining attorney who is reviewing it against federal law and existing marks. The first office action or approval usually follows within a few months. Monitor TSDR for the examiner's first action. No filing is required until an office action or other requirement is issued.
Need help with SEPTERNA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
San Francisco, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Shane Rumbaugh
Shane Rumbaugh Rumbaugh Law PLLC2400 Ansys Drive, Suite 102Canonsburg, PA 15317United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemical and chemical reagents for testing and characterizing G protein-coupled receptors (GPCRs), for scientific or medical research use; chemical reagents for use in genetic research | ACTIVE | — |
| 005 | Pharmaceutical preparations for modulating G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; pharmaceutical preparations for use in neurology, endocrinology, metabolism, immunology, oncology, cardiovascular medicine, gastroenterology, pain, anesthesiology, dermatology, ophthalmology, psychiatry, pulmonology, urology, reproductive medicine, and orthopedics; pharmaceutical preparations and substances that are used alone or in combination with other pharmaceuticals, preparations or substances, and that act on various GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; chemical and biochemical preparations and substances for medical purposes for treatment and/or diagnosis of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders; pharmaceutical preparations for targeting GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; biological preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders | ACTIVE | — |
| 040 | Custom manufacture of biochemical systems, namely, custom manufacture of systems for targeting G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; custom manufacturing for others, namely, manufacturing of pharmaceutical preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 29, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 26, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 20, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 20, 2026 | NWAP | NEW APPLICATION ENTERED | — |